| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Brian L. Stauffer | Q48302717 |
| Mihai Gheorghiade | Q60059386 | ||
| Bertram Pitt | Q63107334 | ||
| Gerasimos Filippatos | Q63107352 | ||
| Javed Butler | Q63107356 | ||
| Stefan D. Anker | Q30310195 | ||
| Burkert Pieske | Q79439304 | ||
| Saame Raza Shaikh | Q91208930 | ||
| Adriaan A Voors | Q91537232 | ||
| Hani N Sabbah | Q114291627 | ||
| Stephen J Greene | Q125217678 | ||
| Justin B Perry | Q125252956 | ||
| Mitchell E Allen | Q125252961 | ||
| David A Brown | Q125252963 | ||
| John Cleland | Q44931654 | ||
| Wilson S Colucci | Q46618620 | ||
| P2860 | cites work | Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. | Q46686975 |
| Heart failure: mitochondrial dysfunction and oxidative stress in CHF. | Q46810978 | ||
| Redox-dependent increases in glutathione reductase and exercise preconditioning: role of NADPH oxidase and mitochondria | Q46837795 | ||
| Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease | Q46863176 | ||
| Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy | Q46873061 | ||
| Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies | Q46975964 | ||
| Developing New Treatments for Heart Failure: Focus on the Heart | Q48115739 | ||
| Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study | Q48570168 | ||
| Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure | Q48748873 | ||
| NCLX is an essential component of mitochondrial Na+/Ca2+ exchange | Q22254831 | ||
| 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration | Q22306346 | ||
| ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...] | Q22306349 | ||
| Respiratory complex III is required to maintain complex I in mammalian mitochondria | Q24322645 | ||
| Opening and closing the metabolite gate | Q24569785 | ||
| How mitochondria produce reactive oxygen species | Q24643882 | ||
| Antioxidants prevent health-promoting effects of physical exercise in humans | Q24646248 | ||
| Mitochondrial DNA mutations in human disease | Q24676881 | ||
| Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies | Q26801166 | ||
| Antioxidants improve the phenotypes of dilated cardiomyopathy and muscle fatigue in mitochondrial superoxide dismutase-deficient mice | Q26822994 | ||
| Maternal inheritance of mitochondrial DNA by diverse mechanisms to eliminate paternal mitochondrial DNA | Q26849450 | ||
| Mitochondrial dysfunction in heart failure | Q26851293 | ||
| Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? | Q26853254 | ||
| Mitochondria as a therapeutic target in heart failure | Q27005632 | ||
| The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore | Q28241418 | ||
| Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death | Q28242653 | ||
| Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants | Q28281746 | ||
| Dimers of mitochondrial ATP synthase form the permeability transition pore | Q28287824 | ||
| Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death | Q28297152 | ||
| Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein | Q28377109 | ||
| Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis | Q28383442 | ||
| Individual Cardiac Mitochondria Undergo Rare Transient Permeability Transition Pore Openings | Q36654820 | ||
| Ketones Step to the Plate: A Game Changer for Metabolic Remodeling in Heart Failure? | Q36783575 | ||
| Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy | Q36837270 | ||
| Perspectives in innate and acquired cardioprotection: cardioprotection acquired through exercise | Q36843601 | ||
| Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation | Q36870637 | ||
| Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury | Q36999928 | ||
| Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy | Q37091220 | ||
| Targeting lipophilic cations to mitochondria. | Q37148517 | ||
| Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart | Q37151412 | ||
| Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism | Q37154013 | ||
| Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. | Q37170429 | ||
| PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart | Q37189947 | ||
| The molecular composition of the mitochondrial permeability transition pore | Q37195017 | ||
| Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness | Q37197868 | ||
| Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial | Q37213020 | ||
| The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases | Q37229784 | ||
| Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure | Q37238298 | ||
| Mitochondria in cardiac hypertrophy and heart failure | Q37246892 | ||
| (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. | Q37248486 | ||
| Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure | Q37297827 | ||
| Mitochondria-targeted antioxidants in the treatment of disease | Q37348550 | ||
| An attempt to prevent senescence: a mitochondrial approach. | Q37374360 | ||
| Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides | Q37375934 | ||
| The role of the mitochondrial permeability transition pore in heart disease. | Q37376953 | ||
| Heart failure enhances susceptibility to arrhythmogenic cardiac alternans | Q37393007 | ||
| Cardiolipin remodeling in the heart | Q37412214 | ||
| Mitochondrial calcium transport in the heart: physiological and pathological roles | Q37414637 | ||
| Redox modification of ryanodine receptors underlies calcium alternans in a canine model of sudden cardiac death. | Q37422595 | ||
| Cardiac metabolism in heart failure: implications beyond ATP production. | Q37495811 | ||
| Why do we still not have cardioprotective drugs? | Q37511439 | ||
| Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis | Q37526796 | ||
| Human mitochondrial DNA: roles of inherited and somatic mutations | Q37648855 | ||
| Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension | Q37686149 | ||
| NADPH oxidases and cardiac remodelling | Q37775558 | ||
| Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. | Q50519099 | ||
| Malonyl CoA: A promising target for the treatment of cardiac disease. | Q51750613 | ||
| Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction. | Q52852855 | ||
| Myocardial adenine nucleotide concentrations and myocardial norepinephrine content in patients with heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. | Q53025853 | ||
| Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity. | Q53486283 | ||
| Protein kinase A catalytic subunit alters cardiac mitochondrial redox state and membrane potential via the formation of reactive oxygen species. | Q53569175 | ||
| Expression of the cytoplasmic domain of beta1 integrin induces apoptosis in adult rat ventricular myocytes (ARVM) via the involvement of caspase-8 and mitochondrial death pathway. | Q53617151 | ||
| Inhibition of mitochondrial permeability transition pores by cyclosporine A improves cytochrome C oxidase function and increases rate of ATP synthesis in failing cardiomyocytes. | Q53629275 | ||
| Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. | Q54442411 | ||
| Mitochondrial production of reactive oxygen species contributes to the β-adrenergic stimulation of mouse cardiomycytes. | Q54597053 | ||
| Effect of N-2-mercaptopropionyl glycine on exercise-induced cardiac adaptations. | Q54614124 | ||
| Mitochondria-Targeted Antioxidant MitoQ 10 Improves Endothelial Function and Attenuates Cardiac Hypertrophy | Q56970686 | ||
| Rationale and Design of the MITOCARE Study: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRO40303 for the Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coro | Q57572076 | ||
| Antioxidant, EUK-8, Prevents Murine Dilated Cardiomyopathy | Q59202829 | ||
| Chronic formoterol administration reduces cardiac mitochondrial protein synthesis and oxidative capacity in mice | Q60324029 | ||
| EUK-8, a Superoxide Dismutase and Catalase Mimetic, Reduces Cardiac Oxidative Stress and Ameliorates Pressure Overload-Induced Heart Failure in the Harlequin Mouse Mutant | Q63412945 | ||
| Serendipity and the discovery of novel compounds that restore mitochondrial plasticity | Q28384256 | ||
| Mitochondria-targeted antioxidant preserves contractile properties and mitochondrial function of skeletal muscle in aged rats | Q28385949 | ||
| The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin | Q28387020 | ||
| Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats | Q28387024 | ||
| Mitochondrial Metabolism in Aging Heart | Q28388306 | ||
| Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation | Q28578053 | ||
| Supercomplex assembly determines electron flux in the mitochondrial electron transport chain | Q28590886 | ||
| Cardiolipin stabilizes respiratory chain supercomplexes | Q29615470 | ||
| Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism | Q29616055 | ||
| 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
| Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management | Q30459704 | ||
| Glutathione oxidation as a trigger of mitochondrial depolarization and oscillation in intact hearts | Q30485060 | ||
| Cardiac myosin activation: a potential therapeutic approach for systolic heart failure | Q30583292 | ||
| Impaired mitochondrial network excitability in failing guinea-pig cardiomyocytes | Q30692654 | ||
| Channel formation by yeast F-ATP synthase and the role of dimerization in the mitochondrial permeability transition | Q33718426 | ||
| ATP flux through creatine kinase in the normal, stressed, and failing human heart | Q33756653 | ||
| Ion transport and energetics during cell death and protection | Q33861202 | ||
| Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia | Q33919143 | ||
| Molecular and cellular basis of viable dysfunctional myocardium | Q33924001 | ||
| Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy | Q33931661 | ||
| Respiratory chain supercomplexes of mitochondria and bacteria | Q33961173 | ||
| Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane | Q33961781 | ||
| Dysregulation of cardiolipin biosynthesis in pediatric heart failure | Q33969031 | ||
| Therapeutic targeting of mitochondrial superoxide in hypertension | Q33981734 | ||
| The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. | Q33984662 | ||
| Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial | Q34046673 | ||
| Uncoupling to survive? The role of mitochondrial inefficiency in ageing | Q34071511 | ||
| Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs | Q34127971 | ||
| Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease | Q34137989 | ||
| Role of mitochondrial dysfunction in cardiac glycoside toxicity | Q34172696 | ||
| Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure | Q37812007 | ||
| Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart. | Q37831555 | ||
| Exercise-induced cardiac preconditioning: how exercise protects your achy-breaky heart | Q37851768 | ||
| What are the costs of heart failure? | Q37868827 | ||
| Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development | Q37884459 | ||
| Mitochondrial inner membrane lipids and proteins as targets for decreasing cardiac ischemia/reperfusion injury | Q38122609 | ||
| Mitochondrial autophagy--an essential quality control mechanism for myocardial homeostasis | Q38132341 | ||
| Regulation of mitochondrial dynamics and cell fate | Q38197491 | ||
| Mitochondria-targeted therapies for acute kidney injury | Q38237988 | ||
| Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart | Q38246367 | ||
| The "Goldilocks Zone" from a redox perspective-Adaptive vs. deleterious responses to oxidative stress in striated muscle | Q38256368 | ||
| Cardiovascular drug development: is it dead or just hibernating? | Q38424497 | ||
| Mitochondrial dynamics: Orchestrating the journey to advanced age. | Q38445626 | ||
| How mitochondrial dynamism orchestrates mitophagy | Q38497008 | ||
| Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets | Q38545752 | ||
| Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. | Q38548171 | ||
| Therapeutic potential of resveratrol in heart failure | Q38552981 | ||
| "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction | Q38585269 | ||
| Mitochondrial Quality Control as a Therapeutic Target | Q38640867 | ||
| Organization and Regulation of Mitochondrial Protein Synthesis | Q38704038 | ||
| Mitochondrial remodeling: Rearranging, recycling, and reprogramming | Q38821544 | ||
| Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial | Q38916981 | ||
| Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? | Q38939243 | ||
| Role of microRNA in metabolic shift during heart failure | Q38981243 | ||
| Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study | Q39174869 | ||
| Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization. | Q39599713 | ||
| Improved systolic function of rat cardiocytes during heart failure by overexpression of SERCA2a | Q39782569 | ||
| Respiratory active mitochondrial supercomplexes. | Q39913363 | ||
| Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications | Q40059081 | ||
| Symbiotic theory of the origin of eukaryotic organelles; criteria for proof | Q40774076 | ||
| Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease | Q40964153 | ||
| Redox-optimized ROS balance: a unifying hypothesis | Q41441153 | ||
| Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes | Q41811834 | ||
| SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery | Q41945438 | ||
| Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans | Q42247172 | ||
| Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man | Q42455774 | ||
| Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium | Q42524047 | ||
| Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy | Q42639640 | ||
| Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. | Q42678131 | ||
| Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). | Q42872754 | ||
| The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. | Q34209536 | ||
| Mitochondrial permeability transition and oxidative stress | Q34232146 | ||
| Cardiac mitochondria and arrhythmias | Q34307966 | ||
| Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity | Q34396286 | ||
| A new twist on an old idea part 2: cyclosporine preserves normal mitochondrial but not cardiomyocyte function in mini-swine with compensated heart failure | Q34399914 | ||
| The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial | Q34441721 | ||
| Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. | Q34447034 | ||
| Selective elimination of mitochondrial mutations in the germline by genome editing | Q34473537 | ||
| Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach | Q34559786 | ||
| Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth | Q34623700 | ||
| What is the mitochondrial permeability transition pore? | Q34658211 | ||
| The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble | Q34807191 | ||
| Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy | Q34822268 | ||
| Calcineurin inhibitor nephrotoxicity | Q34945314 | ||
| Cardiac energy metabolism homeostasis: role of cytosolic calcium | Q34977128 | ||
| The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications | Q35010370 | ||
| Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury | Q35012392 | ||
| Inhibitors of ROS production by the ubiquinone-binding site of mitochondrial complex I identified by chemical screening | Q35064609 | ||
| [Na+]i handling in the failing human heart | Q35090046 | ||
| Altered myocardial calcium cycling and energetics in heart failure--a rational approach for disease treatment | Q35116100 | ||
| Domestication of the cardiac mitochondrion for energy conversion | Q35225761 | ||
| The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work | Q35225766 | ||
| Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury | Q35424798 | ||
| Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy | Q35562060 | ||
| Energy metabolism in heart failure | Q35602060 | ||
| Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium | Q35659510 | ||
| Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection | Q35666876 | ||
| The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat | Q36036237 | ||
| Myocardial substrate metabolism in the normal and failing heart | Q36179008 | ||
| Mitochondrial criticality: a new concept at the turning point of life or death. | Q36293854 | ||
| Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure | Q36304375 | ||
| Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels | Q36319041 | ||
| Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C | Q36341946 | ||
| Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide | Q36366202 | ||
| Adrenaline-induced “oxygen-wastage” and enzyme release from working rat heart. Effects of calcium antagonism, β-blockade, nicotinic acid and coronary artery ligation | Q66981532 | ||
| 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure | Q67593279 | ||
| 31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with Tl-201 myocardial perfusion imaging | Q70676620 | ||
| Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group | Q70733060 | ||
| Fatty acid oxidation enzyme gene expression is downregulated in the failing heart | Q71828329 | ||
| Effect of pressure development on oxygen consumption by isolated rat heart | Q72218889 | ||
| Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy | Q72331370 | ||
| Sodium and the heart: a hidden key factor in cardiac regulation | Q73158153 | ||
| Vitamin E supplementation and cardiovascular events in high-risk patients | Q73365511 | ||
| Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium | Q73427285 | ||
| [Cardiac energy metabolism in heart valve diseases with 31P MR spectroscopy] | Q73661799 | ||
| p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta -adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation | Q73689040 | ||
| Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy | Q73932420 | ||
| Human myocardial ATP content and in vivo contractile function | Q74453126 | ||
| Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans | Q74561897 | ||
| Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies | Q74615255 | ||
| 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy | Q74764934 | ||
| Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism | Q77393474 | ||
| Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium | Q78151171 | ||
| Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease | Q78744696 | ||
| Influence of beta-adrenoceptor blockade on the myocardial accumulation of fatty acid tracer and its intracellular metabolism in the heart after ischemia-reperfusion injury | Q79297944 | ||
| The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease | Q80357440 | ||
| Reduced in vivo skeletal muscle oxygen consumption in patients with chronic heart failure--a study using Near Infrared Spectrophotometry (NIRS) | Q81502572 | ||
| Catecholamine-induced cardiac mitochondrial dysfunction and mPTP opening: protective effect of curcumin | Q82600646 | ||
| Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV | Q83409915 | ||
| Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury | Q83618914 | ||
| Novel mitochondria-targeted antioxidants: plastoquinone conjugated with cationic plant alkaloids berberine and palmatine | Q84356843 | ||
| Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart | Q84838077 | ||
| Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart | Q85606383 | ||
| Catechin ameliorates cardiac dysfunction in rats with chronic heart failure by regulating the balance between Th17 and Treg cells | Q87741148 | ||
| Treatment of mitochondrial disorders: antioxidants and beyond | Q88199066 | ||
| Mitochondria as a drug target in ischemic heart disease and cardiomyopathy | Q36426316 | ||
| Heart failure with preserved ejection fraction: chronic low-intensity interval exercise training preserves myocardial O2 balance and diastolic function | Q36531058 | ||
| Mitochondrial ROS-induced ROS release: an update and review | Q36531183 | ||
| Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure | Q36550830 | ||
| Role of cardiolipin alterations in mitochondrial dysfunction and disease | Q36561388 | ||
| Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart | Q36605039 | ||
| Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. | Q36654675 | ||
| Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction | Q43124905 | ||
| 'Leaky' ryanodine receptors and sudden cardiac death | Q43264886 | ||
| Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction | Q43542921 | ||
| Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone | Q43564490 | ||
| Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy | Q43912543 | ||
| The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction | Q43935007 | ||
| Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged | Q44009242 | ||
| Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts | Q44071888 | ||
| Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy | Q44182277 | ||
| Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway | Q44306725 | ||
| Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy | Q44454565 | ||
| Exercise training preserves coronary flow and reduces infarct size after ischemia-reperfusion in rat heart | Q44560614 | ||
| Mitochondrial abnormalities in myocardium of dogs with chronic heart failure | Q44576578 | ||
| Effects of edaravone on reperfusion injury in patients with acute myocardial infarction | Q45027825 | ||
| Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure | Q45886178 | ||
| Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. | Q45921765 | ||
| Mitochondrial Na+/Ca2+-exchanger blocker CGP37157 protects against chromaffin cell death elicited by veratridine. | Q45976080 | ||
| Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina | Q46137371 | ||
| In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease | Q46212051 | ||
| Coenzyme Q10: an independent predictor of mortality in chronic heart failure | Q46239711 | ||
| Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging | Q46425737 | ||
| Effect of cyclosporine on reperfusion injury in acute myocardial infarction | Q46453592 | ||
| Metabolic response of the human heart to inotropic stimulation: in vivo phosphorus-31 studies of normal and cardiomyopathic myocardium | Q46508744 | ||
| Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia | Q46650374 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| Kearns-Sayre syndrome | Q2605012 | ||
| mitochondrial myopathy | Q6881881 | ||
| heart mitochondria | Q70188839 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 238-250 | |
| P577 | publication date | 2016-12-22 | |
| 2017-04-01 | |||
| P1433 | published in | Nature Reviews Cardiology | Q2108444 |
| P1476 | title | Expert consensus document: Mitochondrial function as a therapeutic target in heart failure | |
| P478 | volume | 14 |
| Q58693386 | A high-fat diet impairs mitochondrial biogenesis, mitochondrial dynamics, and the respiratory chain complex in rat myocardial tissues |
| Q47248786 | AMPKα2 Protects Against the Development of Heart Failure by Enhancing Mitophagy via PINK1 Phosphorylation |
| Q50860951 | ATP5J and ATP5H Proactive Expression Correlates with Cardiomyocyte Mitochondrial Dysfunction Induced by Fluoride. |
| Q52333566 | Activation of Class I histone deacetylases contributes to mitochondrial dysfunction in cardiomyocytes with altered complex activities. |
| Q89964336 | Age and Sex Differences in Hearts of Soluble Epoxide Hydrolase Null Mice |
| Q41509997 | Aging: Molecular Pathways and Implications on the Cardiovascular System. |
| Q89708268 | Alteration of cardiolipin biosynthesis and remodeling in single right ventricle congenital heart disease |
| Q39429565 | Altered Mitochondrial Metabolism and Mechanosensation in the Failing Heart: Focus on Intracellular Calcium Signaling |
| Q88661222 | Analyses of Mitochondrial Calcium Influx in Isolated Mitochondria and Cultured Cells |
| Q61814382 | AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism |
| Q42651346 | Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia. |
| Q64108165 | Association between admission plasma 2-oxoglutarate levels and short-term outcomes in patients with acute heart failure: a prospective cohort study |
| Q63352498 | Associations of Mitochondrial and Nuclear Mitochondrial Variants and Genes with Seven Metabolic Traits |
| Q98568564 | Bedaquiline inhibits the yeast and human mitochondrial ATP synthases |
| Q57036069 | Bid maintains mitochondrial cristae structure and protects against cardiac disease in an integrative genomics study |
| Q91795773 | Bioenergetics and translational metabolism: implications for genetics, physiology and precision medicine |
| Q92890117 | Cardiac monoamine oxidases: at the heart of mitochondrial dysfunction |
| Q91625884 | Cardiac troponin T is associated with mortality in patients admitted to critical care in a UK major trauma centre: a retrospective database analysis |
| Q58715795 | Cardiomyocytes cultured on mechanically compliant substrates, but not on conventional culture devices, exhibit prominent mitochondrial dysfunction due to reactive oxygen species and insulin resistance under high glucose |
| Q64239449 | Cardiorenal protective effect of sodium-glucose cotransporter 2 inhibitors and mitochondrial function |
| Q89146570 | Changes in the activity of some metabolic enzymes in the heart of SHR rat incurred by transgenic expression of CD36 |
| Q88008254 | Current themes in myocardial and coronary vascular aging |
| Q94560908 | Danqi Pill Protects Against Heart Failure Post-Acute Myocardial Infarction via HIF-1α/PGC-1α Mediated Glucose Metabolism Pathway |
| Q90821719 | Deficiency of nuclear receptor interaction protein leads to cardiomyopathy by disrupting sarcomere structure and mitochondrial respiration |
| Q92644691 | Denervation drives skeletal muscle atrophy and induces mitochondrial dysfunction, mitophagy and apoptosis via miR-142a-5p/MFN1 axis |
| Q60047543 | Disease Tolerance and Pathogen Resistance Genes May Underlie Persistence and Differential Progression to Chagas Disease Cardiomyopathy |
| Q45073605 | Docosahexaenoic acid lowers cardiac mitochondrial enzyme activity by replacing linoleic acid in the phospholipidome. |
| Q57293272 | Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials |
| Q64236310 | Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production |
| Q92781615 | Early myopathy in Duchenne muscular dystrophy is associated with elevated mitochondrial H2 O2 emission during impaired oxidative phosphorylation |
| Q64081792 | Elamipretide Improves Mitochondrial Function in the Failing Human Heart |
| Q93013975 | Female Heart Health: Is GPER the Missing Link? |
| Q54088960 | G protein-coupled estrogen receptor (GPER) deficiency induces cardiac remodeling through oxidative stress. |
| Q64244369 | High-resolution respirometry in human endomyocardial biopsies shows reduced ventricular oxidative capacity related to heart failure |
| Q47141564 | Human Cardiac 31P-MR Spectroscopy at 3 Tesla Cannot Detect Failing Myocardial Energy Homeostasis during Exercise |
| Q92895912 | Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism |
| Q51763166 | Improved Cardiovascular Function in Old Mice after N-Acetyl Cysteine and Glycine Supplemented Diet: Inflammation and Mitochondrial Factors. |
| Q95325890 | Increasing carbohydrate oxidation improves contractile reserves and prevents hypertrophy in porcine right heart failure |
| Q93082044 | Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes |
| Q90259003 | Influence of mitochondrial and systemic iron levels in heart failure pathology |
| Q49300240 | Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy |
| Q50660284 | Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge. |
| Q47158357 | Integration of miRNA and gene expression profiles suggest a role for miRNAs in the pathobiological processes of acute Trypanosoma cruzi infection |
| Q92283486 | Irreversible oxidative post-translational modifications in heart disease |
| Q90720520 | Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies |
| Q64946361 | Kruppel-Like Factor 4 (KLF4) and its Regulation on Mitochondrial Homeostasis. |
| Q90744789 | LAMP-2B regulates human cardiomyocyte function by mediating autophagosome-lysosome fusion |
| Q91909836 | Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving TT-SR microstructural remodeling |
| Q42373740 | MMI-0100 Inhibits Cardiac Fibrosis in a Mouse Model Overexpressing Cardiac Myosin Binding Protein C. |
| Q47163241 | Melatonin Efficacy in Obese Leptin-Deficient Mice Heart |
| Q90420571 | Melatonin in Heart Failure: A Promising Therapeutic Strategy? |
| Q93192737 | Metabolic remodeling induced by mitokines in heart failure |
| Q42333907 | Metabolomics and Cardiology: Toward the Path of Perinatal Programming and Personalized Medicine |
| Q93347609 | Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease |
| Q103029040 | MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction |
| Q58611546 | Mitochondria as a therapeutic target for common pathologies |
| Q93385793 | Mitochondria-Targeted Drugs |
| Q91826141 | Mitochondrial 4-HNE derived from MAO-A promotes mitoCa2+ overload in chronic postischemic cardiac remodeling |
| Q98951973 | Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy |
| Q92267248 | Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction |
| Q90679359 | Mitochondrial Quality Control in the Heart: New Drug Targets for Cardiovascular Disease |
| Q90319225 | Mitochondrial dysregulation and muscle disuse atrophy |
| Q89397986 | Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials |
| Q50281263 | Mitochondrial genome variability: the effect on cellular functional activity. |
| Q90395114 | Mitochondrial membrane transporters and metabolic switch in heart failure |
| Q64058959 | Mitofusin 2 Participates in Mitophagy and Mitochondrial Fusion Against Angiotensin II-Induced Cardiomyocyte Injury |
| Q90663952 | Mitophagy in Cardiovascular Diseases |
| Q63446889 | Multiscale structure-function relationships in right ventricular failure due to pressure overload |
| Q52715720 | Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. |
| Q45064238 | New and revisited approaches to preserving the reperfused myocardium |
| Q38671402 | Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model |
| Q90077681 | Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure: a retrospective cohort study |
| Q92921857 | Peripheral Blood Mononuclear Cells and Platelets Mitochondrial Dysfunction, Oxidative Stress, and Circulating mtDNA in Cardiovascular Diseases |
| Q92356186 | Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine |
| Q89746482 | Platelet mitochondrial DNA methylation predicts future cardiovascular outcome in adults with overweight and obesity |
| Q92063996 | Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease |
| Q91666914 | Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts |
| Q47956238 | Protein turnover in the failing heart: an ever-changing landscape |
| Q97645720 | Pyrroloquinoline quinone can prevent chronic heart failure by regulating mitochondrial function |
| Q64123698 | Quantitative temporal analysis of protein dynamics in cardiac remodeling |
| Q92293076 | Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failur |
| Q39195160 | Redefining the role of biomarkers in heart failure trials: expert consensus document |
| Q55334029 | Reduced ejection fraction heart failure - new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments. |
| Q47770905 | Regulation of mitochondrial bioenergetics by the non-canonical roles of mitochondrial dynamics proteins in the heart |
| Q92702018 | Sarcopenia and Heart Failure |
| Q92475887 | Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? |
| Q42371471 | Spermine and spermidine reversed age-related cardiac deterioration in rats |
| Q64081816 | Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work? |
| Q91276580 | Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles |
| Q89641857 | Targeting the Mitochondria in Heart Failure: A Translational Perspective |
| Q64084319 | Telomerase Deficiency Predisposes to Heart Failure and Ischemia-Reperfusion Injury |
| Q60950146 | Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models |
| Q41056656 | The Involvement of Mg2+ in Regulation of Cellular and Mitochondrial Functions |
| Q92469179 | The New Promise of Mitochondrial Transplantation for Myocardial Recovery |
| Q64087497 | The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis |
| Q97587345 | The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats |
| Q57155941 | The effects of metabolic substrate availability on human adipose stem cell spheroid survival |
| Q64084317 | Three in a Box: Understanding Cardiomyocyte, Fibroblast, and Innate Immune Cell Interactions to Orchestrate Cardiac Repair Processes |
| Q59136280 | Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure |
| Q90253350 | TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study |
| Q97645771 | Use of cardiac magnetic resonance to detect changes in metabolism in heart failure |
| Q63976707 | Variable outcomes of human heart attack recapitulated in genetically diverse mice |
Search more.